Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

February 1, 2026

Conditions
Obesity
Interventions
DRUG

Semaglutide Injectable Product (not provided by the study)

"Study Procedure:~Subjects that are to be started on semaglutide by their physician will be invited to participate in the study. If the subject is eligible and signs the consent form they will be enrolled in the study. There are three (3) study visits including Baseline/Visit 1 (prior to starting semaglutide), Visit 2 (at week 2-4) and Visit 3 (at week 18-20). The subjects undergo these tests at each visit: weight circumference measured, BMR testing, thermal imaging of BAT, and perform a 24 hour food recall."

Trial Locations (1)

90095

RECRUITING

UCLA Health, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER